What's Happening

Stay up to date on pharmaceutical developments, industry issues, and what’s happening with Healthesystems

Events

Healthesystems’ conferences and speaking engagements

WCI Annual Conference

August 21-24, 2022 in Orlando Florida

Visit Healthe in booth #913 to learn more about our workers’ comp pharmacy & ancillary benefits

RISKWORLD

April 30 - May 3, 2023 | atlanta, Ga

Visit Healthe in booth #1336

Tony Brown, Healthesystems Director of Information Technology, will speak on Tuesday, May 2 at 11 a.m. in the Innovation Hub (Booth #1956) on Prioritizing Cyber Security Strategies Amid the IT Talent Gap.

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Aspruzyo Sprinkle (ranolazine) extended release granules

Approval Date: Feb 2022

Note: New Product

Indicated for the treatment of chronic angina, a type of chest pain caused by reduced blood flow to the heart.

hello world!

Norliqva® (amlodipine) oral solution

Approval Date: Feb 2022

Note: New Product

A peppermint-flavored solution indicated for the treatment of hypertension and angina. Amlodipine is available as a generic in oral tablets.

hello world!

Fleqsuvy (baclofen) oral suspension

Approval Date: Feb 2022

Note: New Product

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

hello world!

Sovaldi (sofosbuvir) tablets

Approval Date: Jan 2022

Note: First-Time Generic

Indicated for the treatment of Hepatitis C genotypes 1-4 in patients without cirrhosis, or with compensated cirrhosis as part of a combination antiviral treatment regimen.

hello world!

Quviviq (daridorexant) tablets

Approval Date: Jan 2022

Note: New Product

Indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

hello world!

Apretude (cabotegravir) extended-release injection suspension

Approval Date: Dec 2021

Note: New Product

Indicated to reduce the risk of HIV-1 infection

hello world!

Rezvoglar (insulin glargine-aglr) injection

Approval Date: Dec 2021

Note: New Product, Biosimilar

Indicated to improve glycemic control for type 1 and 2 diabetes

hello world!

Yusimry (adalimumab-aqvh) injection

Approval Date: Dec 2021

Note: New Product, Biosimilar

The 7th biosimilar approved for adalimumab. For the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

hello world!

Eprontia (topiramate) oral solution

Approval Date: Nov 2021

Note: New Product

Indicated for the treatment of seizures, and for the preventive treatment of migraine

hello world!

Amitiza (lubisprostone) capsules

Approval Date: Nov 2021

Note: First-Time Generic

Indicated for the treatment of opioid-induced constipation

hello world!

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmenucross-circle